H1N1 VLP influenza vaccine: Final Phase II data

Novavax previously reported preliminary data from the first stage of the trial showing that single doses of 15 and 45 µg of the

Read the full 238 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE